A service of arranging or bringing about contact between an investment manager and an issuer or potential issuer.
LOS ANGELES, July 31, 2019 -- ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Wed., August 7, 2019 at 4:30 p.m. Eastern time to discuss its financial results for the second quarter ended June 30, 2019. The financial results will be...
Tru Niagen (nicotinamide riboside) now available for purchase in 100+ retailers across CanadaLOS ANGELES, July 24, 2019 -- ChromaDex Corp. (NASDAQ:CDXC) announced today its flagship consumer product, Tru Niagen® (nicotinamide riboside) is now available in all...
Renowned Cancer Researcher to Support Ongoing Clinical Studies to Further Demonstrate the Safety and Efficacy of NAD+LOS ANGELES, July 23, 2019 -- ChromaDex Corp. (NASDAQ:CDXC) announced today it has appointed Brunie H. Felding, Ph.D., Associate Professor, Department...
New clinical study shows Niagen® supplementation safe and effective at the recommended daily serving; statistically significant sustained blood NAD+ levelsLOS ANGELES, July 08, 2019 -- ChromaDex Corp. (NASDAQ:CDXC) announced today that the results of its latest...
ChromaDex receives industry award for its safety record and the robust research behind its NAD-boosting ingredient, Tru Niagen (nicotinamide riboside)LOS ANGELES, June 05, 2019 -- ChromaDex Corp. (NASDAQ:CDXC) announced today its flagship consumer product, Tru...
LOS ANGELES, May 15, 2019 -- ChromaDex Corp. (NASDAQ:CDXC) announced today that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Kevin Farr, will present at the 20th Annual B. Riley FBR Investor Conference at the Beverly Hilton Hotel in Beverly...
- First Quarter 2019 Net Revenues Increased by 53% to $10.0 Million - First Quarter 2019 Highlights vs. First Quarter 2018 Strong start to the year with $10.0 million of net sales, higher gross margins and increased marketing efficiencyContinued progress building TRU...
Private Placement Led by High Profile Venture Capitalists and Strategic InvestorsLOS ANGELES, May 09, 2019 -- ChromaDex Corp. (NASDAQ:CDXC) announced today that it has entered into a note purchase agreement for the sale of $10.0 million of convertible notes in a...
LOS ANGELES, May 02, 2019 -- ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Thurs., May 9, 2019 at 4:30 p.m. Eastern time to discuss its financial results for the first quarter ended March 31, 2019. The financial results will be...
Distribution agreement for Tru Niagen (nicotinamide riboside) in Vancouver area provides access to high-end pharmacies and clinicsLOS ANGELES, April 24, 2019 -- ChromaDex Corp. (NASDAQ:CDXC) announced today a new distribution partnership for TRU NIAGEN® with...